RBCC And Therakine Initiate Phase II Of Drug Delivery Development

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB: RBCC) and its joint venture partner, Therakine, Ltd., are pleased to announce that they have reached a major new milestone in the development of a revolutionary new drug delivery technology. This week, the companies reached terms to initiate Phase II of research and analysis on a new injectable, sustained-release technology poised to vastly improve patients’ use of a crucial drug in the fight against drug and alcohol dependence.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC